ファーマフーズ reported results for the fiscal year ended July 2026. Consolidated net sales declined 3.1% year on year to ¥63.223 billion, while operating profit rose 11.2% to ¥2.632 billion. Segment profit improved substantially as the BtoC business increased the efficiency of its advertising expenditure.
ファーマフーズ reported consolidated results for the fiscal year ended July 2026, with net sales of ¥63.223 billion, operating profit of ¥2.632 billion, ordinary profit of ¥2.44 billion and net profit of ¥1.988 billion. Net sales declined 3.1% year on year, while operating profit rose 11.2%.
The BtoC business recorded net sales of ¥55.368 billion, down 2.4% year on year. Advertising expenditure declined 7.4% to ¥33.81 billion as the company promoted more efficient use of advertising and promotional expenses. As a result, BtoC segment profit rose 21.0% to ¥4.481 billion.
By product category, sales of pharmaceuticals and quasi-drugs were ¥43.192 billion, down 0.2% year on year. Cumulative shipments of the Newmo brand reached 32.96 million units, while cumulative shipments of New Z, Newmo V and Newmo Vactory shampoo also increased.
Cosmetics sales were ¥5.542 billion, down 11.3% year on year. The company said that the MATSUGE WMOA eyelash serum was progressing toward recovering its investment. Supplement sales were ¥5.983 billion, down 8.4% year on year, while cumulative shipments of Tamagosamin reached 8.54 million bags.
For the fiscal year ending July 2027, consolidated net sales are forecast at ¥64 billion, operating profit at ¥3 billion, ordinary profit at ¥3.4 billion and net profit at ¥2.2 billion.